The reduction in tuberculosis to be expected from mass BCG vaccination in Britain during the next few years has been assessed. It is concluded that mass BCG vaccination in adolescence should very soon be replaced by a selective vaccination policy aimed at groups at particular risk of exposure to tubercle bacilli.
Summary
The reduction in tuberculosis to be expected from mass BCG vaccination in Britain during the next few years has been assessed. It is concluded that mass BCG vaccination in adolescence should very soon be replaced by a selective vaccination policy aimed at groups at particular risk of exposure to tubercle bacilli. BEFORE we can consider what future BCG vaccination policy should be, we must know both how much tuberculosis there will be to prevent, and how much of it will be preventable by BCG. I shall take the second of these two points first.
It might be thought that there is no question about the efficacy of BCG in preventing tuberculosis. The magic figure of 80%y protective efficacy has been upheld through a series of reports on the MRC trial, and has withstood various dastardly attacks from those outside this country whose experience of BCG vaccination has frankly been disappointing. Few people here would doubt the continuation of the same high efficacy of British BCG in British (and immigrant) schoolchildren. And yet I propose to do just that today.
You have probably seen a Carroll Palmer for these differences (Palmer & Long, 1966) , namely that in populations with much atypical mycobacterial infection, such as the southern United States, and South India, this infection provides a partial natural vaccination, to which BCG can add relatively little. You may remember Dr D'Arcy Hart's (1967) detailed appraisal of this proposition, showing that on available evidence it was inadequate to account for such large differences, and postulating differing potencies of the vaccines used in the various trials, to bridge the remaining gaps.
I first prepared a tabular comparison of these trials myself over 4 years ago and have been looking at it, and lecturing on it, at intervals since. Yet it was only a few weeks ago that an alternative and much simpler explanation for the differences occurred to me (Table 2) .
I have here rearranged the trials in order, according to the amount of tuberculosis developing in the unvaccinated group. The percentage efficacy is almost exactly in step with this order-there is only one reversal. So close a concordance, if the two sets of figures are not associated, has a chance of occurring of only one in 360. Even if you legitimately object that the bottom two trials were made in the same population with vaccine from the same source, and so should be regarded as one, the chance of as close a concordance is still one in sixty. Now this, though intriguing, is not wholly convincing, because there are certainly many other differences between the trials than the amount of tuberculosis experienced by the population; in Between 1960 and 1970 the annual incidence of primary tuberculous infection in the Netherlands for those aged 15 and over decreased from about 150/100,000 to about 40, with an average of about 80/l 00,000 during the period (Styblo, Meijer & Sutherland, 1969, p. 40) . About 5% of young adults develop clinical tuberculosis within 10 years following infection (Sutherland, 1966) , so that the average annual incidence of clinical tuberculosis in unvaccinated subjects was about 4/100,000, or 0 04/1000. This is the required estimate of the annual incidence of tuberculosis in unvaccinated subjects in Britain during the next decade. In his presidential address to the BTTA last week, Dr Springett (1971) made an independent estimate of this incidence, and arrived at the rather larger figure of 0-10/1000 for the net decade.
These two estimates are both just below the lowest figure in Table 2 Nevertheless, mass BCG vaccination must have a very limited future indeed as a control policy in this country. BCG will then retain an importance only in relation to groups at special risk of exposure to tubercle bacilli. Contacts in tuberculous households, medical students and nurses will be joined by the populations of overcrowded areas in our large cities, those going to visit or work in countries overseas with substantial tuberculosis problems, and other similar groups.
In conclusion, it is interesting to reflect how right the Americans have been to eschew a general vaccination scheme and how right they were to introduce selective vaccination schemes in high-risk areas in Chicago and New York; but how very wrong they have been to send their troops to Vietnam without apparently even considering the possibility that BCG would protect them against the very high risk of tuberculous infection they encounter there (Elliott, Spaur & Sokolowski, 1969) . It is fortunate, too, that the MRC trial took place just in time to establish the high efficacy of BCG in the tuberculosis situation which applied in this country in the early 1950s, as otherwise the value of mass vaccination in countries with even larger tuberculosis problems might well have been doubted by the World Health Organization.
